Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director · 10% owner | June 18, 2021 | June 22, 2021 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 09, 2022 | June 10, 2022 |
| Monte Rosa Therapeutics, Inc.GLUE · Entity 4828 | Director · 10% owner | June 28, 2021 | June 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 18, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.55 · Expires 2031-06-17 | Direct | 15,000 |
Reported balance
After 2021-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-18 · Grant · Acquired 15,000 · Balance 15,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders.
CRISPR Therapeutics AG
Report date June 09, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.70 · Expires 2032-06-09 | Direct | 12,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 12,000 · Balance 12,000 F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders.
Monte Rosa Therapeutics, Inc.
Report date June 28, 2021 · Filed June 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital VI, L.P. | 6,799,115 |
Reported balance
After 2021-06-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-06-28 · Conversion · Acquired 6,515,869 · Balance 6,799,115 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage I, L.P. | 2,097,938 |
Last balance in matching sequence
After 2021-06-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-06-28 · Conversion · Acquired 1,940,043 · Balance 1,940,043 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Row 3 · 2021-06-28 · Purchase · Acquired 157,895 · Balance 2,097,938 F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-06-28 · Conversion · Disposed 20,004,280 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Capital VI, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-28 · Conversion · Disposed 3,000,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-06-28 · Conversion · Disposed 4,150,000 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
| Series C convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Versant Vantage I, L.P. | 0 |
Reported balance
After 2021-06-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-06-28 · Conversion · Disposed 2,699,328 · Balance 0 F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date. F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock converted into Common Stock on a 3.5305-for-one basis upon the closing of the Issuer's initial public offering without payment or additional consideration. The Preferred Stock had no expiration date.
F2: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
F3: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. The Reporting Person is a managing member of Versant Vantage I GP-GP, and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2020 Filed Sep 12, 2020 01:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 974 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 12,303 F3 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Side Fund IV, L.P. ("VSF IV"), to its partners. F4 · ownership.nature: These securities are held of record by VSF IV. VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 09, 2020 Filed Sep 12, 2020 01:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | OtherCommon Shares | 164,162 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024943 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,074,817 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital IV, L.P. ("VVC IV"), to its partners. F2 · ownership.nature: These securities are held of record by VVC IV. Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · derivative · entry 17 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2028-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · shares: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F16 · derivative.exercise_date: This option was granted on June 15, 2018 with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. F14 · balance_after: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F12 · ownership.nature: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F14 · ownership.nature: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.62 | $0.00 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · derivative · entry 16 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2027-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · shares: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F15 · derivative.exercise_date: This option was granted on May 31, 2017 with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017. F14 · balance_after: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F12 · ownership.nature: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F14 · ownership.nature: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · derivative · entry 15 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · shares: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F13 · derivative.exercise_date: This option was granted on October 18, 2016 with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016. F14 · balance_after: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F12 · ownership.nature: These options are held of record by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of VVM LLC. Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. F14 · ownership.nature: These options are held of record by the Reporting Person. The Reporting Person is a managing member of VVM LLC. Pursuant to agreements with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 200 | $93.74 | $18,748.00 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 19,135 | $92.98 | $1,779,256.49 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 200 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.73 to $93.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 36,365 | $92.40 | $3,360,162.37 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 19,335 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.73 to $92.725, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,300 | $91.27 | $392,477.34 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 55,700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.73 to $91.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 15,000 | $59.31 | $889,650.00 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 15,000 | $13.62 | $204,300.00 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2020 Filed Sep 4, 2020 01:21 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 30,000 | $14.00 | $420,000.00 |
DisclosureSEC source: 0000899243-20-024201 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These securities are held of record by Thomas Woiwode ("Mr. Woiwode"). Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC ("VVM LLC"). Pursuant to agreements with VVM LLC, Mr. Woiwode is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,718 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023073 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,927 F9 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP-GP. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 5,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023073 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP-GP to its members. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 5,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023073 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,176 F6 · kind: Represents a change in the form of ownership of Versant Ventures VI GP-GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023073 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP to its partners. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023073 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,000 F3 · kind: Represents a change in the form of ownership of Versant Ventures VI GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VI. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:13 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023073 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,197,230 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VI"), to its partners. F2 · ownership.nature: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,718 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022439 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,209 F9 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP-GP. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 5,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022439 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP-GP to its members, pursuant to a Rule 10b5-1 distribution plan. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 5,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022439 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,176 F6 · kind: Represents a change in the form of ownership of Versant Ventures VI GP-GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Ventures VI GP. F7 · ownership.nature: Shares held by Versant Ventures VI GP-GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022439 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ventures VI GP to its partners, pursuant to a Rule 10b5-1 distribution plan. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022439 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,000 F3 · kind: Represents a change in the form of ownership of Versant Ventures VI GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant VI. F4 · ownership.nature: Shares held by Versant Ventures VI GP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 21:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022439 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,497,230 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("Versant VI"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F2 · ownership.direct: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 23:46 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 6,692 | $33.08 | $221,380.06 |
DisclosureSEC source: 0000899243-20-022185 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,797,230 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F4 · ownership.nature: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 23:46 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 883 | $33.08 | $29,210.79 |
DisclosureSEC source: 0000899243-20-022185 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,125,778 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.255, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 23:46 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 5,492 | $33.04 | $181,445.79 |
DisclosureSEC source: 0000899243-20-022185 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,803,922 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F4 · ownership.nature: Shares held by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 23:46 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 725 | $33.04 | $23,952.70 |
DisclosureSEC source: 0000899243-20-022185 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,126,661 F1 · kind: The sale of these shares were effected pursuant to Rule 10b5-1 trading plans adopted by each of Versant Vantage I, L.P. ("Versant Vantage I") and Versant Venture Capital VI, L.P. ("Versant VI"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 42 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 12 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,491 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members, pursuant to a Rule 10b5-1 distribution plan. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,177 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 11 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F16 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members, pursuant to a Rule 10b5-1 distribution plan. F15 · ownership.nature: Shares held by Versant Vantage I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,177 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,177 F14 · kind: Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP. F15 · ownership.nature: Shares held by Versant Vantage I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners, pursuant to a Rule 10b5-1 distribution plan. F12 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,187 F11 · kind: Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I. F12 · ownership.nature: Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 79,217 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,127,386 F9 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("Versant Vantage I"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F10 · ownership.nature: Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,449 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP LP, to its partners, pursuant to a Rule 10b5-1 distribution plan. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 4,131 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 5 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP LP, to its partners, pursuant to a Rule 10b5-1 distribution plan. F4 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 3,098 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 4 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,131 F7 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel. F4 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 57,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 3 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 601,445 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F6 · ownership.nature: Shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 1,033 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,033 F3 · kind: Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I. F4 · ownership.nature: Shares held by Versant Voyageurs I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:54 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | OtherCommon Stock | 192,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000950123-20-007315 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,017,016 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. ("Versant Voyageurs I"), to its partners, pursuant to a Rule 10b5-1 distribution plan. F2 · ownership.nature: Shares held by Versant Voyageurs I. Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board of directors, may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,311 | $83.00 | $440,809.81 |
DisclosureSEC source: 0000899243-20-018703 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 554,190 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.85 to $83.17, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and pursuant to agreement with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 20:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 14,689 | $82.16 | $1,206,920.22 |
DisclosureSEC source: 0000899243-20-018703 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 559,501 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.85 to $82.83, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and pursuant to agreement with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 10,000 | $75.35 | $753,453.00 |
DisclosureSEC source: 0001209191-20-038789 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 574,190 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.25 to $75.63, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and pursuant to agreement with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 23:02 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 10,000 | $72.51 | $725,069.00 |
DisclosureSEC source: 0001209191-20-038789 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 584,190 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.35 to $72.84, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and pursuant to agreement with VVM LLC, the Reporting Person is deemed to hold these securities for the benefit of VVM LLC. Accordingly, VVM LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:17 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $59.70 | $0.00 |
DisclosureSEC source: 0001209191-20-036589 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2020 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2020; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2021 Annual General Meeting of Shareholders. F2 · derivative.underlying_shares: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · balance_after: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: The Reporting Person is a managing member of Versant Venture Management, LLC and pursuant to agreement with Versant Venture Management, LLC, the Reporting Person is deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries C Preferred Stock · Derivative | 1,055,960 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 24 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 350,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F4 · ownership.nature: Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries C Preferred Stock · Derivative | 314,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 23 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 104,407 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F3 · ownership.nature: Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). The Reporting Person may be deemed to beneficially own indirectly 635,309 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, the general partner of Versant Ventures VI GP, the general partner of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP"), the general partner of Versant I Parallel. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries C Preferred Stock · Derivative | 1,370,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 22 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 454,548 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F1 · ownership.nature: Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). The Reporting Person may be deemed to beneficially own indirectly 6,413,332 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP"), the general partner of Versant Ventures VI GP, L.P. ("Versant Ventures VI GP"), the general partner of Versant VI. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), or for any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries C Preferred Stock · Derivative | 2,444,382 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 21 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 810,522 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · price: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F6 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series C Preferred Stock had no expiration date. F7 · ownership.nature: Shares held by Versant Vantage I, L.P. ("Versant Vantage I"). The Reporting Person may be deemed to beneficially own indirectly 810,522 shares of Common Stock by reason of the Reporting Person is a managing member of Versant Vantage I GP-GP, LLC, the general partner of Versant Vantage I GP, L.P., the general partner of Versant Vantage I, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:59 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries B Preferred Stock · Derivative | 1,517,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003364 · doc4.xml · derivative · entry 20 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 503,327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F5 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F4 · ownership.nature: Shares held by Versant Voyageurs I, L.P.("Versant Voyageurs I"). The Reporting Person may be deemed to beneficially own indirectly 2,130,579 shares of Common Stock by reason of the Reporting Person has a beneficial interest in Versant Voyageurs I GP Company, the general partner of Versant Voyageurs I. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.